Single bolus PCSK9 Inhibition: A new approach to plaque stabilisation

被引：0
|
作者：
Nicholls, Stephen J. [1 ]
Manmathan, Gavin PR. [1 ]
机构：
[1] Monash Univ, Victorian Heart Inst, Clayton, Australia
来源：
ATHEROSCLEROSIS | 2024年 / 399卷
关键词：
Lipids; PCSK9; inhibitors; Imaging; Atherosclerosis; EVOLOCUMAB;
D O I：
10.1016/j.atherosclerosis.2024.118628
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse
    Saeed, Anum
    Virani, Salim S.
    Jones, Peter H.
    Ballantyne, Christie M.
    Nambi, Vijay
    JOURNAL OF CLINICAL LIPIDOLOGY, 2018, 12 (05) : 1141 - 1145
  • [22] PCSK9 Inhibition: From Current Advances to Evolving Future
    Liu, Chunping
    Chen, Jing
    Chen, Huiqi
    Zhang, Tong
    He, Dongyue
    Luo, Qiyuan
    Chi, Jiaxin
    Hong, Zebin
    Liao, Yizhong
    Zhang, Shihui
    Wu, Qizhe
    Cen, Huan
    Chen, Guangzhong
    Li, Jinxin
    Wang, Lei
    CELLS, 2022, 11 (19)
  • [23] PCSK9 Inhibition and Risk of Diabetes: Should We Worry?
    Carugo, Stefano
    Sirtori, Cesare R.
    Corsini, Alberto
    Tokgozoglu, Lale
    Ruscica, Massimiliano
    CURRENT ATHEROSCLEROSIS REPORTS, 2022, 24 (12) : 995 - 1004
  • [24] PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia
    Ito, Matthew K.
    Santos, Raul D.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (01) : 7 - 32
  • [25] PCSK9 inhibition and cholesterol homeostasis in insulin producing β-cells
    Paeth, Guenter
    Perakakis, Nikolaos
    Mantzoros, Christos S.
    Seufert, Jochen
    LIPIDS IN HEALTH AND DISEASE, 2022, 21 (01)
  • [26] Key aspects of PCSK9 inhibition beyond LDL lowering
    Ramin-Mangata, Stephane
    Blanchard, Valentin
    Lambert, Gilles
    CURRENT OPINION IN LIPIDOLOGY, 2018, 29 (06) : 454 - 459
  • [27] LDL lowering effect of PCSK9 inhibition is reduced in women
    Myasoedova, Veronika A.
    Rimbert, Antoine
    Camera, Marina
    Le May, Cedric
    Capoulade, Romain
    Cariou, Bertrand
    Poggio, Paolo
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2023, 9 (04) : 337 - 342
  • [28] PCSK9 Inhibition to Reduce Cardiovascular Risk Tempering Expectations
    Waters, David D.
    Hsue, Priscilla Y.
    CIRCULATION RESEARCH, 2017, 120 (10) : 1537 - 1539
  • [29] PCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions
    Hilvo, Mika
    Simolin, Helena
    Metso, Jari
    Ruuth, Maija
    Oorni, Katariina
    Jauhiainen, Matti
    Laaksonen, Reijo
    Baruch, Amos
    ATHEROSCLEROSIS, 2018, 269 : 159 - 165
  • [30] PCSK9 Inhibition and Risk of Diabetes: Should We Worry?
    Stefano Carugo
    Cesare R. Sirtori
    Alberto Corsini
    Lale Tokgozoglu
    Massimiliano Ruscica
    Current Atherosclerosis Reports, 2022, 24 : 995 - 1004
12345